Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06895213

Evaluation of Plasma Renin Concentrations in Cardiac Surgery

The purpose of this research is to learn more about how renin (a blood test) is affected by cardiopulmonary bypass, the heart-lung machine used during open heart surgery. Renin is a protein that may be elevated in response to low blood pressure or situations where organs do not receive sufficient oxygen. Renin may potentially be used as an indicator for specific treatments aimed to increase the blood pressure. This study will evaluate blood samples for renin concentration throughout the course of open heart surgery.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cardiac Surgery With Cardiopulmonary Bypass Cardiovascular Diseases Hypotension Pathologic Processes Pathological Conditions, Signs and Symptoms Shock Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location status: Recruiting

Location contact

Patrick M Wieruszewski, Pharm.D.

CONTACT

[email protected]

507-255-5732

About this study

The investigator hypothesizes that renin concentrations will increase with exposure to cardiopulmonary bypass and that increased renin concentrations will be associated with the development of vasoplegia.

Specific Aim 1. To characterize the effects of cardiopulmonary bypass on plasma renin concentrations in adults undergoing cardiac surgery.

Specific Aim 2. To test the prognostic value of plasma renin concentrations on outcomes following cardiac surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult persons 18 years of age or greater.
  • Scheduled for an elective cardiac surgical procedure involving the use of cardiopulmonary bypass.

Exclusion criteria

  • Surgery involving heart or lung transplantation or implant of a durable left ventricular assist device.
  • Emergency cardiac surgery.
  • Established diagnosis of any congenital heart disease.
  • End-stage kidney disease receiving kidney replacement therapy before surgery.

Treatment and study plan

Primary outcomes

  1. Plasma renin concentrations

    Time frame: Up to 24 hours after surgery

Secondary outcomes

  1. Vasoplegia

    Time frame: First 24 hours postoperative

    Requirement of any vasopressor to maintain a mean arterial pressure of 65 mmHg or greater despite a cardiac index of at least 2.2 L/min/m2 with or without the need for pharmacologic inotropy

  2. Acute kidney injury

    Time frame: 7 days

    Assessed by the Kidney Disease Improving Global Outcomes (KDIGO) staging criteria

  3. Organ dysfunction

    Time frame: 28 days

    The presence of any organ support therapy including vasopressors, renal replacement therapy, and mechanical ventilation

  4. Mortality

    Time frame: 28 days

Study contacts

Contact information is provided by the study sponsor or research team.

Patrick M Wieruszewski, Pharm.D.

CONTACT

[email protected]

507-255-5732

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 26, 2025
Registry last updated
May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.